Patents Assigned to Marinomed Biotechnologie GmbH
-
Patent number: 10022449Abstract: The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.Type: GrantFiled: December 17, 2010Date of Patent: July 17, 2018Assignee: MARINOMED BIOTECHNOLOGIE GmbHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Marielle Konig-Schuster
-
Patent number: 9993512Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.Type: GrantFiled: September 30, 2016Date of Patent: June 12, 2018Assignee: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas T. Grassauer, Eva Prieschl
-
Publication number: 20120315311Abstract: Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.Type: ApplicationFiled: August 23, 2012Publication date: December 13, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER, Christiane MEIER, Alexander PRETSCH
-
Publication number: 20120302522Abstract: The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.Type: ApplicationFiled: December 17, 2010Publication date: November 29, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Marielle Konig-Schuster
-
Patent number: 8282969Abstract: A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.Type: GrantFiled: December 4, 2007Date of Patent: October 9, 2012Assignee: Marinomed Biotechnologie GmbHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Koller, Alexander Pretsch
-
Publication number: 20120237572Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus, The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER
-
Publication number: 20120058206Abstract: The present invention relates to pharmaceutical compositions for administration to the respiratory tract, the gastrointestinal tract or the eyes. In particular, the invention relates to liquid formulations and dry powder compositions comprising carrageenan, and in particular iota and kappa carrageenan, and one or more therapeutic agents. These sprays, powders, and the gel that forms when they are administered to the respiratory tract, the gastrointestinal tract or the eyes, have now surprisingly been found to be a very effective way of prevention and treatment of type I allergies and intranasal administration of therapeutic agents.Type: ApplicationFiled: September 19, 2011Publication date: March 8, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER
-
Publication number: 20110224160Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as in contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated autoimmune diseases, Hashimoto's thyroiditis, Sjogren's disease, adrenalitis, polymyositis, or pernicious anemia.Type: ApplicationFiled: November 16, 2009Publication date: September 15, 2011Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Eva Prieschl-Grassauer, Thomas Friedrich
-
Publication number: 20110091583Abstract: The present invention relates to pharmaceutical compositions based on carrageenan as an active ingredient, for use as a medicament in the prophylactic or therapeutic treatment of allergic conditions or diseases, with the proviso that the carrageenan comprises iota- and/or kappa-carrageenan and is substantially free of lambda carrageenan. Typically, the invention relates to liquid formulations, gels and dry powder compositions comprising iota- and/or kappa-carrageenan and, optionally, one or more non-carrageenan therapeutic agents for administration to the respiratory tract, the gastrointestinal tract or the eyes. The compositions of the invention have been found to be efficacious in the prevention and treatment of type I allergies and additionally, may exert an adjuvant function upon combined mucosal administration with non-carrageenan therapeutic agents.Type: ApplicationFiled: June 30, 2009Publication date: April 21, 2011Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer
-
Publication number: 20110059919Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.Type: ApplicationFiled: August 22, 2008Publication date: March 10, 2011Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer
-
Publication number: 20100227830Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment diseases mediated or caused by activated granulocytes, preferably a type I or type III allergy or septic shock.Type: ApplicationFiled: August 3, 2007Publication date: September 9, 2010Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl
-
Publication number: 20100160254Abstract: The present invention provides the use of a polymer for the manufacture of an antiviral pharmaceutical composition for the treatment of a rhinovirus infection, wherein the polymer is cellulose sulfate.Type: ApplicationFiled: March 30, 2007Publication date: June 24, 2010Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Alexander Pretsch
-
Publication number: 20100040658Abstract: A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.Type: ApplicationFiled: December 4, 2007Publication date: February 18, 2010Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Alexander Pretsch
-
Publication number: 20090298792Abstract: The present invention provides the use of cellulose sulfate or chitosan for the manufacture of an anti-inflammatory pharmaceutical or cosmetic composition for the treatment of inflammation.Type: ApplicationFiled: March 30, 2007Publication date: December 3, 2009Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Christiane Meier
-
Publication number: 20080131454Abstract: The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.Type: ApplicationFiled: December 5, 2006Publication date: June 5, 2008Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Alexander Pretsch